Skip to main content

IL-8 is a novel marker for breast cancer


Estrogen receptor (ER) status is an important parameter in breast cancer management as ER-positive breast cancers have a better prognosis than ER-negative tumors. This difference comes essentially from the lower aggressiveness and invasiveness of ER-positive tumors.


Here, we demonstrate that IL-8 is clearly overexpressed in most ER-negative breast cell lines and breast tumor samples tested. We have also performed a large clinical study on breast tumor samples to determine whether IL-8 expression could be correlated with other clinical parameters. In addition, in vitro studies show that the invasion potential of ER-negative breast cancer cells is associated at least in part with expression of IL-8, but not with IL-8 receptor levels. Moreover, IL-8 increases the invasiveness of ER-positive breast cancer cells, thus confirming the invasion-promoting role of IL-8. Overexpression of IL-8 in ER-negative breast cancer cells involves a high transcriptional activity of the IL-8 promoter. By analysing the IL-8 promoter, we have identified the elements responsible for IL-8 overexpression in ER-negative breast cancer cells.


Taken together, these results provide the basis for the control of IL-8 expression in breast cancer and define IL-8 as a novel marker of breast cancers.

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Cite this article

Chavey, C., Freund, A., Durand, S. et al. IL-8 is a novel marker for breast cancer. Breast Cancer Res 7 (Suppl 2), P4.11 (2005).

Download citation

  • Published:

  • DOI:


  • Breast Cancer
  • Breast Cancer Cell
  • Breast Cell
  • Invasion Potential
  • Cancer Management